Adrenal Insufficiency

Nephrology
17
Pipeline Programs
2
Companies
2
Clinical Trials
16
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
16
Early DiscoveryClinical DevelopmentMarket

On Market (16)

Approved therapies currently available

U
ACTICORTApproved
hydrocortisone
Unknown Company
topical1981
U
ALA-CORTApproved
hydrocortisone
Unknown Company
topical1973
U
ALKINDI SPRINKLEApproved
hydrocortisone
Unknown Company
Corticosteroid [EPC]oral2020
U
BALNEOL-HCApproved
hydrocortisone
Unknown Company
topical1982
U
BETA-HCApproved
hydrocortisone
Unknown Company
topical1988
U
DERMACORTApproved
hydrocortisone
Unknown Company
topical
U
EPICORTApproved
hydrocortisone
Unknown Company
topical
U
FLEXICORTApproved
hydrocortisone
Unknown Company
topical
U
GLYCORTApproved
hydrocortisone
Unknown Company
topical1983
U
HC (HYDROCORTISONE)Approved
hydrocortisone
Unknown Company
topical1973
U
HI-CORApproved
hydrocortisone
Unknown Company
topical1973
U
HYDRO-RXApproved
hydrocortisone
Unknown Company
for rx compounding1978
U
HYDROCORTISONEApproved
hydrocortisone
Unknown Company
topical1978
U
HYTONEApproved
hydrocortisone
Unknown Company
topical1972
U
KHINDIVIApproved
hydrocortisone
Unknown Company
Corticosteroid [EPC]oral2025
U
NOGENIC HCApproved
hydrocortisone
Unknown Company
topical1988

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
hydrocortisonePhase 2/32 trials
Active Trials
NCT03013166Completed3,000Est. Dec 2016
NCT00915343Completed64Est. Jan 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Takedahydrocortisone
Takedahydrocortisone

Clinical Trials (2)

Total enrollment: 3,064 patients across 2 trials

NCT00915343Takedahydrocortisone

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Start: Aug 2007Est. completion: Jan 200964 patients
Phase 2/3Completed
NCT03013166Takedahydrocortisone

THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone

Start: Sep 2016Est. completion: Dec 20163,000 patients
N/ACompleted

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)